Business Wire

Mundipharma Welcomes the New Guidelines from ESC/EASD Recommending First-Line use of Sodium-Glucose Co-transporter-2 Inhibitors for Type 2 Diabetes Patients with Cardiovascular Disease

Share

As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), the Mundipharma network of independent associated companies welcomes the news that the sodium-glucose co-transporter-2 inhibitor (SGLT2i) class, which includes canagliflozin, has now been recommended in the newly published 2019 ESC (European Society of Cardiology) Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD (European Association for the Study of Diabetes) as a first-line treatment option for the management of patients with type 2 diabetes mellitus (T2DM), either drug naïve or on metformin, with atherosclerotic cardiovascular disease (ASCVD) or high/very high cardiovascular (CV) risk, which includes patients with other target organ damage (i.e. damage to the kidneys as predicted by important markers such as proteinuria and eGFR) and multiple other risk factors.1 Furthermore, SGLT2is are also recommended as a first-line treatment for patients with T2DM at high risk of heart failure (HF).1 The new guidelines were presented yesterday at the 2019 ESC Congress in Paris, France and have been published in the European Heart Journal.1

The updated guidelines took into account data from CV outcomes trials for SGLT2is which have demonstrated a range of CV benefits across the class. This includes the positive CV outcomes data for canagliflozin from the CANVAS Programme.2

The guidelines now recommend SGLT2is as a first-line treatment option for the prevention and management of chronic kidney disease (CKD) for patients with T2DM, who have a high associated risk of CV disease.1 Nephroprotection has been observed in recent CV outcome trials, including the CREDENCE study, which found canagliflozin plus standard of care reduced the relative risk of the primary renal and cardiovascular outcomes compared with placebo plus standard of care.3 Canagliflozin is currently under review by the European Medicines Agency (EMA) to extend its licence for use in the T2DM with CKD patient population.

“It is exciting to see that the recent positive results from CV outcomes trials of SGLT2is in patients with type 2 diabetes have been reflected in the updated ESC/EASD guidelines,” commented Professor Antonio Ceriello, Head of Diabetes Research Department, IRCCS MultiMedica, Milan, Italy. “It is important for clinicians to now recognise that initiating an SGLT2i, such as canagliflozin, as a first line therapy in patients with certain types of CV disease, or target organ damage, may improve long-term patient outcomes.”

Approximately 58 million people in Europe currently live with T2DM, which is set to rise to 67 million by 2045.5 If left untreated, patients are at greater risk of developing serious health complications, such as renal disease, HF, and CV disease which is the most common cause of death for T2DM patients.4

“Cardiovascular disease is a major complication of type 2 diabetes which puts patients’ lives at risk and is a significant burden on healthcare systems across Europe. With the new guidelines, clinicians can make the best treatment decisions and transform the standard of care for their patients.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma.

The updated guidelines can be viewed at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Diabetes-Pre-Diabetes-and-Cardiovascular-Diseases-developed-with-the-EASD.

-END-

Notes to the editors:

About the Guidelines1
The European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) convened a panel to update the existing guidelines, published in 2013, on the management of diabetes, pre-diabetes and cardiovascular diseases. The updated guidelines were published in the European Heart Journal and were presented during the annual meeting of ESC in Paris, France, on the 2nd September 2019.

About Invokana®6
Invokana® (canagliflozin) is an oral, once-daily medication which belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2, which promotes the loss of glucose via the urine, lowering blood glucose levels in adults with T2DM. Invokana was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of diabetes. Approval was based on a comprehensive global Phase III clinical trial programme.

About Vokanamet®7
Vokanamet® (a fixed-dose combination of canagliflozin and metformin) is approved in the European Union for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Vokanamet combines two oral glucose-lowering medicinal products with different and complementary mechanisms of action.

About the CANVAS Programme2
The CANVAS Programme (N=10,142) comprised the two large canagliflozin cardiovascular outcome trials, CANVAS and CANVAS-R, and included a pre-specified integrated analysis of these two studies to evaluate the potential for CV protection of canagliflozin in patients with T2DM who had either a prior history of CV disease or at least two CV risk factors. The integrated analysis also evaluated the effects of canagliflozin on renal and safety outcomes.

Canagliflozin met the primary outcome by significantly reducing the rates of the composite of major adverse CV events (MACE) comprised of CV mortality, non-fatal myocardial infarction (MI), or non-fatal stroke (26.9 vs. 31.5/1000 patient-years, hazard ratio (HR) 0.86; 95% confidence interval (CI 0.75-0.97; P<0.0001 for non-inferiority; P=0.0158 for superiority) compared with placebo plus standard of care, respectively. All 3 components of MACE composite (CV death, non-fatal MI, and non-fatal stroke) exhibited point estimates of effect suggesting benefit with canagliflozin.

Adverse events reported in the CANVAS Programme were generally consistent with the known safety profile of canagliflozin. Whilst an increase in lower limb amputation and bone fractures were observed in the CANVAS Programme, this signal was not observed in further long term clinical trial data involving high risk patients.3

About the CREDENCE Clinical Trial3
The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and fully recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a phase 3 randomised, double-blind, event-driven, placebo-controlled, parallel-group, 2 arm multi-centre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

About the Mundipharma network
Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.

Invokana® and Vokanamet® are registered trademarks of Janssen

References:


1 European Society of Cardiology (ESC). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2019);00,1-69.

2 Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine (2017);377:644-657.

3 Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephrology. The New England Journal of Medicine. 2019; 380(24): 2295-2306.

4 Fan, W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology & Metabolism. 2017;6(1):8-16.

5 IDF Diabetes Atlas Eighth Edition 2017. Available at: http://diabetesatlas.org/resources/2017-atlas.html. Last accessed September 2019.

6 Invokana SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/invokana-epar-product-information_en.pdf Last accessed September 2019

7 Vokanamet SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors 20/European_Commission_final_decision/WC500206514.pdf. Last accessed September 2019

Job code: MBL/DIAB-19025
Date of preparation: September 2019

Contact information

Cendrine Banerjee-Quetel
Asset Communications Associate, Mundipharma International Ltd
Email: Cendrine.Banerjee-Quetel.external@mundipharma.com
Tel: +44 (0) 1223 393 009

Abbie Bell
Senior Account Manager, Havas SO
E-mail: HavasSO-Mundipharma@havasso.com
Tel: +44 (0) 20 3196 9919
Mob: +44 7375 660 515

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GSMA: ICT Industry Agrees Landmark Science-based Pathway to Reach Net Zero Emissions27.2.2020 11:30:00 EETPress release

The ICT industry is today taking an unprecedented step forward in tackling climate change with the release of the first-ever science-based pathway to reduce Greenhouse Gas (GHG) emissions across the telecoms sector. This supports the GSMA’s commitment to helping the mobile industry achieve Net Zero carbon emissions by 2050. The new Science-Based Target (SBT) is the result of a collaboration between the ITU, GeSI, the GSMA, and SBTi to develop a sector-specific decarbonisation pathway that allows ICT companies to set targets in line with the latest climate science. It includes emissions reductions trajectories for mobile, fixed and data centre operators to meet the ambitious Paris Agreement goal of limiting global warming to 1.5°c, designed to substantially reduce the risks and effects of climate change. Twenty nine operator groups representing 30 per cent of global mobile connections are already committed to SBTs. These include America Movil, AT&T, BT, Bharti Airtel, Deutsche Telekom,

KA Imaging’s X-ray Detector Allows Any X-ray System to Be Upgraded to Dual-Energy27.2.2020 11:00:00 EETPress release

Canadian manufacturer KA Imaging is preparing to launch Reveal, a premium x-ray detector that upgrades any x-ray system to Dual-Energy. “Reveal is the ideal retrofit solution as it will fit into any ISO standard size tray”, explains Amol Karnick, president and CEO of KA Imaging. Thanks to this feature, the cost of implementation can be reduced to a fraction of the price: whereas conventional dual exposure dual-energy systems can cost as high as half a million dollars, KA Imaging’s Reveal can be obtained at a quarter of this price. “You can simply replace your old detector with Reveal, as it will work with any conventional portable or fixed x-ray source”, continues Amol. The competitive pricing strategy is just one of the advantages. KAI developed a unique technology that can improve dual-energy x-ray images. Reveal is the world’s first portable digital detector capable of separating different energy levels with a single exposure. It delivers three images: traditional DR, soft tissue an

The Success of ReSound Technology Is Amplified and Multiplied for Even More People With Hearing Loss27.2.2020 11:00:00 EETPress release

GN Hearing, the innovation leader in hearing aid technology, today launches a range of exciting new ReSound hearing aid solutions, a move which is in line with the company’s continuous strategic focus on innovation leadership, as communicated as part of the strategy for 2020 and beyond. No matter the degree of hearing loss, the new solutions aim to solve the key listening challenges of people with hearing loss where and when they need it most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005323/en/ (Photo: Business Wire) Globally, 466 million people have a disabling hearing lossii. GN Hearing wants to help every person with hearing loss improve their hearing and live each day to the full. This extensive launch testifies to GN Hearing’s innovation leadership and dedication to helping people with all types of hearing loss, thanks to its leading sound quality, connectivity and customer care. “We are now taking the first

Orange and SES Team up on O3b mPOWER Communications System and Open a New Era for Satellite Connectivity Innovation27.2.2020 10:50:00 EETPress release

Orange, one of the world’s leading multi-service telecommunications operators and present in 18 countries in Africa, will be the first telco to adopt the ground-breaking O3b mPOWER, SES’s next-generation Medium Earth Orbit (MEO) satellite communications system, to exponentially ramp up its consumer and business services, starting in the Central African Republic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226006105/en/ Orange and SES Team up on O3b mPOWER Communications System and Open a New Era for Satellite Connectivity Innovation (Photo: Business Wire) O3b mPOWER is the world’s only fully-funded non-geostationary orbit (NGSO) broadband system in development today. Positioned at only 8,000 kilometres away from Earth, the system will power low-latency high-throughput solutions that can be seamlessly integrated into existing terrestrial networks. When operational in 2022, O3b mPOWER will provide multiple terabits of th

NXP Semiconductors Expands Global Use of the Workiva Platform to Gain Efficiencies and Reduce Risk27.2.2020 10:00:00 EETPress release

Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, today announces that Netherlands-based NXP Semiconductors uses the Workiva platform to streamline filings with the U.S. Securities and Exchange Commission and to modernize its Sarbanes Oxley Act (SOX) processes. “We use the Workiva platform to save time in our reporting processes and create efficiencies across our entire finance organization,” said Bryan Moiles, Assistant Corporate Controller at NXP. “We have teams in the Netherlands and the U.S., and the Workiva platform is the only solution that allows me to run a 24-hour clock where I don't have to worry about version control.” With Workiva, Moiles and his team create automatic updates, track every change and seamlessly collaborate with colleagues around the world in real time to create trusted reports and regulatory filings. “The Workiva platform is our one source of truth for all our reports,” said Moiles. “Because everything is linked

DSB to Divest Spare Part Workshops27.2.2020 10:00:00 EETPress release

Due to structural changes DSB is investigating the market with a view to divesting the activities at the workshops which deliver and maintain spare parts for the trains. Until 2030, Fremtidens Tog (Future Trains) will gradually replace the train sets that DSB is currently operating. This implies that DSB will no longer have the same need to operate its own spare part workshops. Besides, DSB’s coming generation of electric train sets, Fremtidens Tog, are to be maintained by the train supplier and not by DSB, meaning that DSB will have fewer options to redeploy staff from the spare part workshops. Therefore DSB is now transferring the areas of Supply, Logistics & Refurbishment to an independent company to investigate a divestment to a private third party in collaboration with SEB Corporate Finance. As part of this potential transaction, DSB will enter into an agreement with the divested company for delivery and maintenance of spare parts until 2024 with an extension option. As an indepen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom